Trial
NCT01307956
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University of Nebraska
Collaborators
National Cancer Institute (NCI)
Condition
Adenocarcinoma of the Gastroesophageal Junction
Intervention
Fluorouracil
Why stopped
Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-26